NextCure, Inc. Gains 34.25%
NextCure, Inc. (NXTC:NASDAQ) rocketted at $14.11, a gain of 34.3%. On Mon, Nov 24, 2025, NXTC:NASDAQ hit a New 2-Week High of $14.11. The stock appeared on our News Catalysts scanner on Thu, Nov 20, 2025 at 10:06 AM in the 'MISCELLANEOUS' category. From Mon, Nov 10, 2025, the stock recorded 70.00% Up Days and 54.55% Green Days
About NextCure, Inc. (NXTC:NASDAQ)
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.
Top 10 Gainers:
- Leap Therapeutics, Inc. (LPTX:NASDAQ), 368.57%
- Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 109.09%
- Pasithea Therapeutics Corp. (KTTA:NASDAQ), 46.48%
- ZJK Industrial Co., Ltd. (ZJK:NASDAQ), 40.68%
- Blue Foundry Bancorp (BLFY:NASDAQ), 40.03%
- Agroz Inc. (AGRZ:NASDAQ), 36.79%
- Binah Capital Group, Inc. (BCG:NASDAQ), 34.55%
- NextCure, Inc. (NXTC:NASDAQ), 34.25%
- Inspire Veterinary Partners, Inc. (IVP:NASDAQ), 33.33%
- Planet Green Holdings Corp. (PLAG:NYSEMKT), 30.77%